Last updated on February 2019
Safety Study Of Tofacitinib Versus Tumor Necrosis Factor (TNF) Inhibitor In Subjects With Rheumatoid Arthritis
Brief description of study
This post-marketing study is designed to compare the safety of tofacitinib versus TNF inhibitor with respect to major cardiovascular adverse events and malignancies, excluding non-melanoma skin cancers when given to subjects with rheumatoid arthritis. Other safety events, including non-melanoma skin cancers, hepatic events, infections, and efficacy parameters will be collected and evaluated in the study.
Clinical Study Identifier: NCT02092467
Start Over
Pfizer CT.gov Call Center
Mestska nemocnice Ostrava, Radiologie a zobrazovaci metody (rentgen) Ostrava, Czechia0.36miles
Connect »